ABC-DLBCL, which is characterized by constitutive activation of nuclear factor-kappa B (NF-κB), is thought to be the most aggressive subtype, and patients with ABC-DLBCL have a poorer clinical outcome with an approximated 40% overall survival rate compared to those with primary mediastinal B-cell lymphoma or germinal-center B-cell-like-DLBCL (Roschewski et al., 2014; Sehn and Gascoyne, 2015). This evidence concerns the gene NFKB1 and aneurysmal bone cyst.